Repository logo
 
Publication

Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis

2016-06Journal article Open access
Simple item page
dc.contributor.authorStein, A
dc.contributor.authorSchwenke, C
dc.contributor.authorFolprecht, G
dc.contributor.authorArnold, D
dc.date.accessioned2016-11-30T20:59:19Z
dc.date.available2016-11-30T20:59:19Z
dc.date.issued2016-06
dc.description.abstractBACKGROUND: The administration and intensity of bevacizumab-based maintenance therapy after induction treatment with bevacizumab is still a matter of debate. Thus, the present meta-analysis and an indirect comparison were performed to clarify these issues. PATIENTS AND METHODS: Trials evaluating a separately defined "maintenance phase," with randomization after the induction phase, were selected. Three trials of maintenance with bevacizumab with or without a fluoropyrimidine (CAIRO3, SAKK 41/06, and AIO KRK 0207) were analyzed regarding the effect on progression-free survival (PFS) and overall survival (OS) of any maintenance therapy compared with observation alone and different maintenance intensities (bevacizumab with or without fluoropyrimidine) compared with observation alone and between each other. RESULTS: Maintenance with bevacizumab with or without fluoropyrimidine after bevacizumab-based induction treatment for 4 to 6 months significantly improved PFS (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.43-0.75; P = .0004) and showed a trend toward prolonged OS (HR, 0.89; 95% CI, 0.78-1.02; P = .09) compared with observation alone. The effect on PFS increased with the intensity of the maintenance regimen (HR, 0.72; 95% CI, 0.60-0.85 for single-agent bevacizumab vs. HR, 0.45; 95%, CI 0.39-0.51 for combination therapy, both compared to observation alone). In contrast, the HRs for OS remained in the same range. A similarly improved PFS (HR, 0.63; 95% CI, 0.50-0.79) was shown for the more intensive maintenance therapy (bevacizumab and fluoropyrimidine) compared with bevacizumab alone. CONCLUSION: Bevacizumab-based maintenance therapy after induction chemotherapy with bevacizumab significantly improves PFS and showed a trend toward prolonged OS and should thus be considered, in particular, in patients with a response to induction treatment.pt_PT
dc.identifier.citationClin Colorectal Cancer. 2016 Jun;15(2):e29-39.pt_PT
dc.identifier.doi10.1016/j.clcc.2015.12.005pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.26/16559
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectBevacizumabpt_PT
dc.subjectNeoplasias Colorrectaispt_PT
dc.subjectMetástasespt_PT
dc.subjectColorectal Neoplasmspt_PT
dc.subjectNeoplasm Metastasispt_PT
dc.titleEffect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysispt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPagee39pt_PT
oaire.citation.issue2pt_PT
oaire.citation.startPagee29-39pt_PT
oaire.citation.volume15pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy.pdf
Size:
1.61 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Saúde - CUF - Infante Santo - Artigos Científicos
ICO - Artigos
Saúde - CUF - Descobertas - Artigos Científicos